EPIMATCopy

• DRUGBANK - Aripiprazole
• indication:

  For the treatment of schizophrenia and related psychotic disorders.

• pharmacology:

• mechanism:

  Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

• toxicity:

• absorprion:

• halflife:

  75-146 hours

• roouteelimination:

  Less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.

• volumedistribution:

  * 4.9 L/kg

• clearance: